
Ardelyx (ARDX) Stock Forecast & Price Target
Ardelyx (ARDX) Analyst Ratings
Bulls say
Ardelyx is well positioned for long-term growth, with successful commercial execution on both IBSRELA and XPHOZAH and the potential additional revenue streams from label expansions and new indications in CIC. The company's strong financial position, with a reported $264.7 million in cash and equivalents, allows it to invest in the future growth of its pipeline and continue to innovate in the biopharmaceutical market. The recent patent approval and commencement of dosing in a Phase 3 trial for IBSRELA in CIC also add to the company's long-term potential.
Bears say
Ardelyx is facing potential risks, such as failure to execute commercially and increasing competition from generic and branded players, which could impact shares. Additionally, while Ardelyx has a significant opportunity in the 2L market for IBS-C, with limited competition for its non-secretagogue drug Ibsrela, there is also a risk of competitors emerging in the future. Furthermore, while current specialty pharmacy relationships are crucial for driving performance, retail pharmacies may be less incentivized to fill prescriptions for non-generic drugs.
This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares